# Pipeline Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pipeline-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.pipelinetherapeutics.com
- Total disclosed funding: $110M
- Latest round: Series C (Feb 11, 2021)
- Investors on record: 12

## About

Based in California, US, and founded in 2017, Pipeline Therapeutics Inc. operates as a biotechnology company that develops small molecules neuroregeneration that includes synaptogenesis, remyelination, and axonal repair. In 2018, Carmine Stengone was appointed as the president and CEO. Mr. Stengone also served as the President & CEO of Avelas Biosciences, Senior Vice President, Business Development for COI Pharmaceuticals, Vice President of Corporate Development for Afraxis Holdings, co-founder and CEO of Afraxis, Inc., Senior Director of Business Development of Phenomix Corporation, and serve a position in Anadys Pharmaceuticals and Johnson & Johnson Pharmaceutical Research and Development.

The company is comprised of scientific & clinical advisors and scientist to develop PIPE-505, a small molecule gamma-secretase inhibitor (GSI) that treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy. It also develops PIPE-307, a neuro-generation process that focuses on remyelination and axonal repair that address a range of neurological disorders including multiple sclerosis. The company also offers a portfolio of programs that provides treatment for neurological disorders and conditions.

The company's revenue is generated by offering its product that focuses on small molecules in neuro-regeneration such as Synaptogenesis, Remyelination, and Axonal Repair.

## Funding rounds

- Series C, Feb 11, 2021, $80M — Versant Ventures, Casdin Capital, Sectoral Asset Management, Suvretta Capital Management, Franklin Templeton, Hadean Ventures, RBV Capital, Perceptive Advisors, Brace Pharma Capital, Samsara BioCapital, Red Tree Venture Capital, Helicase Venture
- Series B, Dec 18, 2019, $30M — Versant Ventures, Sectoral Asset Management, Hadean Ventures, RBV Capital, Brace Pharma Capital

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series B, Series C
- Sectoral Asset Management (https://capitalatlas.ai/funds/sectoral-asset-management) — Series B, Series C
- Hadean Ventures (https://capitalatlas.ai/funds/hadean-ventures) — Series B, Series C
- RBV Capital — Series B, Series C
- Brace Pharma Capital (https://capitalatlas.ai/funds/brace-pharma-capital) — Series B, Series C
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series C
- Suvretta Capital Management — Series C
- Franklin Templeton (https://capitalatlas.ai/funds/franklin-templeton) — Series C
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series C
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series C
- Red Tree Venture Capital (https://capitalatlas.ai/funds/red-tree-venture-capital) — Series C
- Helicase Venture (https://capitalatlas.ai/funds/helicase-venture) — Series C